Checkpoint inhibitors may have greater potential efficacy in tumors with higher PD-L1 expression, so while these data do not prove the impact of substrate metabolism on immunogenicity in melanoma cells, they do directly link tumor cell substrate metabolism to immunogenicity status. This evidence concerns the gene CD274 and neoplasm.